627 results about "Inflammatory cell" patented technology

The present invention relates to methods for treating inflammation in body tissues. More specifically, certain disclosed methods relate to selectively inducing apoptosis in inflammatory immune cells by heating cells for a sufficient time and at a sufficient temperature to induce programmed cell death. The disclosed stents can be placed in contact with the inflammatory cells and heated under controlled conditions. The disclosed apparatus and methods are particularly suitable for treating athersclerotic plaques.

The present invention is directed to an integrated system and a method for utilizing the system to detect and remove blood-borne factors of interest, such as pathogens and/or toxins and/or cytokines, from blood or serum (blood) by contacting the blood with a solid, essentially nonporous substrate which has been surface treated with molecules or chemical groups (the adsorbent media or media) having a binding affinity for the pathogens and/or toxins to be removed (the adsorbents). The invention can be used to remove virulence factors, e.g. toxins, that are released from various pathogens. In one aspect, the invention is for the treatment of sepsis and infection, such as infections associated with battle field trauma.

The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein/and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.

A polymeric biomaterial that facilitates cell-specific ingrowth. The polymeric biomaterial encourages the ingrowth of cell types while reducing the ingrowth of undesirable cell types. This activity encourages proper integration of prosthetic implants or scaffolds utilizing this biomaterial by discouraging encapsulation or the accumulation of inflammatory cells such as macrophages, while encouraging infiltration by desirable cells such as endothelial or smooth muscle cells. Short peptide sequences are included in a polymeric biomaterial that result in complementary activities. Peptide sequences that are specifically cleaved by proteases found within preferred cells are used to cross-link the biomaterial and lead to degradation by those cells. Peptide sequences taken from proteins involved in cell adhesion can also be attached to the biomaterial to encourage adhesion by preferred cells. Combined use of both peptides in the polymeric biomaterial provides both specific adhesion and selective ingrowth.

The present invention relates (a) to new compounds represented by Formula I:

wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, V represents an anti-inflammatory steroid or nonsteroid subunit, or an antineoplastic or antiviral subunit and L represents a linking group covalently linking M and V; (b) to their pharmacologically acceptable salts, prodrugs and solvates, (c) to processes and intermediates for their preparation, and (d) to their use in the treatment of inflammatory/neoplastic/viral diseases and conditions in humans and animals.

The present invention relates to methods for the detection and therapy of inflamed tissue, whereby immune modulators are used to increase the uptake of diagnostic or therapeutic compositions by inflammatory cells.

This disclosure concerns methods for evaluating inflammatory cells and modulators of the inflammatory response in tumor tissue and other relevant tissue types. The methods entail: obtaining a tissue sample and processing said tissue sample to produce histologic slides of tissue sections; staining of the tissue sections to identify inflammatory cells and modulators of the inflammatory response; digitizing slides to produce an image of the stained tissue sections; digitally stratifying the tissue sample into tumor and other relevant tissue compartments; and using digital image analysis to quantify cell-based and cell population-based features. The quantification of cell-based and cell population-based features within a tissue compartment of interest is used to develop a summary score of the immune system-tissue compartment of interest interaction. Patient stratification and selection as candidates for a therapeutic approach is ultimately based on the summary score value.

The current invention relates to a process for increasing the efficacy of cancerous disease inhibiting therapeutic agents delivered to a treatment region of a tissue structure, such as a tumor. The multi-step procedure takes advantage of the resulting thermal stress response occurring as a result of exposure to the cold. Coordinating the thermal related stress response with the timing of cancerous disease inhibiting agent action provides a unique therapeutic regiment to treat tumors which provides a maximized effect on the tumor, protects normal cells, and activates local pro-inflammatory cells.

The present invention provides methods and compositions to modulate inflammation and inflammatory responses using Netrin polypeptides and Netrin receptors. Methods of the present invention comprise the use of Netrin polypeptides and Netrin receptors to decrease migration of inflammatory cells of the immune system to a site of injury or infection.

The present invention relates (a) to new compounds represented by Formula I:

wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, S represents a steroid subunit (steroid moiety) derived from steroid drug with anti-inflammatory activity and L represents a linker molecule linking M and S, (b) to their pharmacologically acceptable salts, prodrugs and solvates, (c) to processes and intermediates for their preparation, and (d) to their use in the treatment of inflammatory diseases and conditions in humans and animals. Such compounds inhibit many cytokines and immune mediators involved in immune responses which cause inflammation, allergy, or alloimmunity, including without limitation IL-1, 2, 4, 5, 6, 10, 12, GMCSF, ICAM, and TNF-α. Importantly, anti-inflammatory steroids exert a direct anti-inflammatory effect through binding to the glucocorticosteroid receptor.

The present invention provides methods or kits with inflammatory cytokines to pretreat 1-ISCs to augment their immune modulatory effect, in prevention and treatment of various diseases such as multiple sclerosis, arthritis, lupus, sepsis, hepatitis, cirrhosis, Parkinson's disease, chronic infections, and GvHD. The present invention relates to novel methods for enhancing the immunosuppressive or the immune stimulatory activities of mesenchymal stem cells (JvfSCs).

The present invention provides for uses of an anti-TNFα antibody or an antigen-binding fragment thereof for the manufacture of a medicament for use in the treatment of asthma or airway inflammation in an individual in need thereof. The present invention also provides for use of an anti-TNFα antibody or an antigen-binding fragment thereof for the manufacture of a medicament for use in reducing accumulation in lungs of inflammatory cells in an individual in need thereof.

An ophthalmological device comprises an implant member carrying an antifibrotic agent that is released slowly over a prolonged period when inserted into a wound in an eye produced by surgery. The member is placed in the vicinity of a wound created during the surgery to inhibit inflammatory cell proliferation, thereby preventing the growth of fibrous tissue after the eye surgery.

A method is provided for the isolation of endothelial progenitor cells from a source of progenitor cells by isolating a population of lineage-negative cells and further isolating CD34⁺ cells from the lineage-negative population by fluorescence-activated cell sorting. Isolated populations of endothelial progenitor cells and therapeutic compositions containing CD34⁺ cells for the induction of blood vessels, induction of angiogenic responses in surrounding blood vessels and the chemotaxis of inflammatory cells are also provided.

The invention provides a cell detection segmentation system and method based on a deep learning neural network. A deep learning method is used for detecting a cell pathological image. Normal cells, inflammatory cells, trichomonad cells, atrophy cells, HPV viruses and other cells in the picture are segmented out. Each type is marked and the number of each type is counted. A judgment is made as to whether a patient is infected or inflammatory or not and reliable and efficient auxiliary diagnosis is provided for pathologists. The invention has the advantages of simplicity, effectiveness, less required hardware configuration and low implementation cost.

The invention discloses a dexamethasone-entrapped macrophage-derived microvesicle as well as a preparation method and application thereof. The dexamethasone-entrapped macrophage-derived microvesicle is formed by entrapping dexamethasone by a microvesicle from a cell RAW 264.7 of a mouse macrophage system. The dexamethasone-entrapped macrophage-derived microvesicle disclosed by the invention can beuptaken by an injured cell more effectively, and fulfills the aim of improving the kidney inflammation by inhibiting the activation of a proinflammatory signal pathway and infiltration of inflammatory cells. Meanwhile, the preparation method disclosed by the invention is simple, convenient and efficient; the prepared microvesicle is from the cell RAW 264.7, so that sufficient microvesicles can beprovided, and the microvesicles are wide in source; large-scale production can be implemented. The dexamethasone-entrapped macrophage-derived microvesicle prepared through the preparation method disclosed by the invention can be applied to preparation of a drug or preparation for treating kidney diseases and can also be applied to preparation of an anti-inflammatory or immunosuppression drug or preparation.